LUNGevity Foundation

LUNGevity, the nation’s leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.

[LUNGevity Foundation @LUNGevity]

🏁The LungXperience is about to enter its final lap!🏁

With our commitment to educate and bring lung cancer awareness to all communities, we have traveled the nation this spring and summer sharing facts about lung cancer. Learn more: https://t.co/Cpm4rYLf0Z

[LUNGevity Foundation @LUNGevity]

August is full of opportunities to connect and learn through virtual events! From music therapy to policy updates, there is something for everyone this month. All virtual events are free to attend but advance registration is required. Sign up now: https://t.co/oqKLGJrKs8 #lcsm

[LUNGevity Foundation @LUNGevity]

@JFire_0 Yes! For more information on making a donation and other ways to give, please visit: https://t.co/1BirYE7MN4

[LUNGevity Foundation @LUNGevity]

Today is #WorldLungCancerDay!

📣Share these facts on social media and have your friends and family share, too!

🫁Sign up for Breathe Deep TOGETHER: https://t.co/r14nrHDBKD

🏳️Join us for Every Breath Forward! https://t.co/QQcq873VIS

Help us make an impact! #lcsm

[LUNGevity Foundation @LUNGevity]

LUNGevity works to ensure all ppl with lung cancer have access to the best care, including clinical trials. Our new paper includes practical recommendations from experts to streamline clinical trial assessments. Read it here in Clinical Lung Cancer: https://t.co/HnWaZScLJr

[LUNGevity Foundation @LUNGevity]

We are excited to announce Team LUNGevity has been selected as a charity partner for the 2027 Double TCS London Marathon, making us a partner for seven of the eight Abbott World Marathon Majors.

Applications are due by August 16 https://t.co/sL459hnbGC

[LUNGevity Foundation @LUNGevity]

FDA approval alert!

On July 22, 2026, the US FDA approved zidesamtinib for adults with advanced NSCLC whose tumors have ROS1 mutations, expanding treatment options for patients with this type of lung cancer. Learn more here: https://t.co/tuqQbmu7i2

[LUNGevity Foundation @LUNGevity]

Before lung cancer entered her life, 24-year-old Camila Bermudez Garcia was focused on building her future.

Read Camila's story in our latest blog: https://t.co/pctWTILyMN

#lungcancer #lcsm #patientstory #advocacy

[LUNGevity Foundation @LUNGevity]

World Lung Cancer Day is Saturday, August 1st!

Make an impact in the lung cancer community by registering for Breathe Deep TOGETHER! https://t.co/dFsgKhS7aJ

Events are happening in Chicago, Columbus, Boston, DC, NYC or participate from anywhere!

Join our meaningful walk to honor loved ones, enjoy family friendly activities, and a resource fair.

Start your team and invite family, friends, and neighbors to join you today!

[LUNGevity Foundation @LUNGevity]

How is the immunotherapy landscape in #NSCLC evolving beyond established ICI-based approaches? Drs. @LealTiciana, @BenCreelan & @JuliaRotow discuss biomarkers, treatment selection, and emerging options in this #ASCO26 program with @PeerView: https://t.co/lO43HFJeY9 #MedEd

[LUNGevity Foundation @LUNGevity]

MET-altered #NSCLC adds new layers of complexity to testing and treatment decisions. Hear Drs. Jonathan W. Goldman, D. Ross Camidge (@DRCamidge), and Xiuning Le (@LeXiuning) share practical approaches to MET testing and real-world management with @PeerView https://t.co/eiQSV5Kxrw

[LUNGevity Foundation @LUNGevity]

ICYMI, check out lung cancer research highlights:

- from the 2026 AACR conference

- from the 2026 ASCO conference

... and get ready for the World Conference on Lung Cancer from Sept. 12-15 in Seoul, Korea.

Stay current on lung cancer news: https://t.co/1gqHt0KnpZ

[LUNGevity Foundation @LUNGevity]

Dr. Arthi Sridhar wants you to know that clinical trials should be considered at every step in a patient's care, not just as an option after other treatments have been exhausted.Hear more from Dr. Sridhar in the latest podcast episode: https://t.co/P2FccpdrAS

#lcsm #lungcancer

[LUNGevity Foundation @LUNGevity]

Navigating treatment choices across the EGFRm #NSCLC continuum? Hear Drs. Natasha B. Leighl, Pasi A. Janne, and Joshua Sabari (@JSabari) share real-world sequencing and decision insights in this #ASCO26 program from @PeerView ➡️ https://t.co/HjgWLYMmVy

[LUNGevity Foundation @LUNGevity]

Earlier this week, LUNGevity responded to the OMB proposed rule on federal financial assistance expressing our concerns and recommending that the rule be rescinded. We are committed to protecting science on behalf of the lung cancer community. https://t.co/m1mWsx4D1L

[LUNGevity Foundation @LUNGevity]

Happy Birthday, America!

[LUNGevity Foundation @LUNGevity]

Data presented at ASCO 2026 reported the unprecedented progression-free survival (7 years) in advanced ALK+ NSCLC. This showcases the promise of precision medicine. And it encourages reseachers -- to keep going!

Get more lung cancer news from #ASCO26 https://t.co/7u5eUyrOKE

[LUNGevity Foundation @LUNGevity]

It’s not too late to register and earn your Abbott World Marathon Major star! Run Sydney with Team LUNGevity and turn your race into a powerful force for progress, raising awareness and funds for lung cancer research, support, and advocacy that are giving more people the chance to live longer, fuller lives.

Athletes at all levels are welcome, learn more by visiting https://t.co/feHTLb17aQ

[LUNGevity Foundation @LUNGevity]

What is peripheral neuropathy and how does it affect people living with lung cancer?

Watch our virtual workshop with @aileenbrassard, ACNP-BC, AOCNP, (@UTMDAnderson) to learn about causes and symptoms of neuropathy, treatment options, how to limit the impact of neuropathy, and more. https://t.co/wIab07OdfP

[LUNGevity Foundation @LUNGevity]

Take a break from the summer heat and join us for a virtual meetup this July! Make new friends, share your experience, and find support.

Virtual meetups are happening every week - sign up now: https://t.co/oqKLGJrKs8